Continuing with this series of case-based podcasts we've done in partnership with LUNGevity, we'll again have a series of experts offer their own perspective to another challenging scenario. All are with the same format of me hosting and presenting the case to Drs. Bob Doebele from University of Colorado and Jyoti Patel from Northwestern University, who participated in the live webinar version of this, then followed in the recording by other terrific colleagues of mine weighing on the same case. These experts are:

• Dr. Suresh Ramalingam, from Winship Cancer Center, Emory University in Atlanta, GA,
• Dr. Jonathan Goldman, from Premier Oncology in Santa Monica, CA.
• Dr. Julie Brahmer, from Sydney Kimmel Cancer Center at Johns Hopkins University, in Baltimore, MD
• Dr. Heather Wakelee, from Stanford University Cancer Center in Palo Alto, CA
• Dr. Karen Reckamp, from City of Hope Cancer Center in Duarte, CA

This case is of a woman with a tumor that is in the range that is smaller than that for which we would routinely recommend post-operative (adjuvant) chemotherapy to reduce the risk of recurrence, but the tumor has some higher risk features that lead her, and might lead us, to be more inclined to recommend it despite the smaller size of the tumor (which is still within a pretty debatable range). Here's the links to the audio and video versions of the podcast, along with the transcript:

[powerpress]

adjuvant-chemo-for-smaller-nsclc-tumor-with-high-risk-features-audio-podcast

adjuvant-chemo-for-smaller-nsclc-tumor-with-high-risk-features-transcript

There are still several more cases coming, on a wide range of topics in lung cancer, so keep looking for those in the coming weeks to months.

Thanks again to LUNGevity for their support, and to our faculty for their time and thoughtful comments.